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Abstract
The elevated glycation of macromolecules by the reactive dicarbonyl and a-oxoaldehyde methylglyoxal (MG) has been
associated with diabetes and its complications. We have identified a rare flavone, fisetin, which increases the level and
activity of glyoxalase 1, the enzyme required for the removal of MG, as well as the synthesis of its essential co-factor,
glutathione. It is shown that fisetin reduces two major complications of diabetes in Akita mice, a model of type 1 diabetes.
Although fisetin had no effect on the elevation of blood sugar, it reduced kidney hypertrophy and albuminuria and
maintained normal levels of locomotion in the open field test. This correlated with a reduction in proteins glycated by MG in
the blood, kidney and brain of fisetin-treated animals along with an increase in glyoxalase 1 enzyme activity and an
elevation in the expression of the rate-limiting enzyme for the synthesis of glutathione, a co-factor for glyoxalase 1. The
expression of the receptor for advanced glycation end products (RAGE), serum amyloid A and serum C-reactive protein,
markers of protein oxidation, glycation and inflammation, were also increased in diabetic Akita mice and reduced by fisetin.
It is concluded that fisetin lowers the elevation of MG-protein glycation that is associated with diabetes and ameliorates
multiple complications of the disease. Therefore, fisetin or a synthetic derivative may have potential therapeutic use for the
treatment of diabetic complications.
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Introduction
The complications of diabetes are the major cause of both
morbidity and mortality in patients with the disease [1], [2].
Chronic hyperglycemia is thought to be a major cause of these
complications and the downstream consequences of hyperglyce-
mia include multiple pathophysiological processes including
protein glycation, reactive oxygen species (ROS) production and
inflammation [3], [4]. We have recently identified and character-
ized the flavonoid fisetin as an orally active neuroprotective and
cognition-enhancing molecule [5]. Fisetin protects nerve cells in
culture from assorted toxic insults including ischemia and
oxidative stress. It has direct antioxidant activity and also increases
the level of the major intracellular antioxidant, glutathione (GSH).
In the context of diabetic complications, GSH is an essential co-
factor for glyoxalase 1 (Glo-1), the rate-limiting enzyme in the
removal of methylglyoxal (MG). Fisetin can also induce the
transcription factor Nrf2 that is associated with the up-regulation
of GSH metabolism and the protection of cells from toxic stress.
Others have found that fisetin has anti-inflammatory activity in
vitro [6], [7]. Although many of these activities of fisetin have the
potential to reduce the metabolic dysfunctions that are associated
with diabetic complications, it is not clear which activities are
relevant in vivo.
Protein glycation, especially by MG, may be a central player in
the complications of diabetes because it has the ability to increase
both inflammation and oxidative stress [8], [9]. Glycation is the
result of the non-enzymatic addition of sugars and toxic aldehydes
such as MG and glyoxal to macromolecules and results in the
formation of advanced glycation end-products (AGEs). Of the
potential glycating agents, MG is the most effective, and its
production is directly coupled to extracellular glucose levels and
therefore the rate of glycolysis [10]. Protein glycation is greatly
enhanced in diabetic tissues, and it has been suggested that
glycation is a major cause of diabetic complications [11], [12].
To test the hypothesis that a compound such as fisetin which
targets multiple pathways associated with hyperglycemia including
MG-dependent protein glycation in vitro can prevent the
complications of diabetes in vivo, we examined the effects of fisetin
on the development of diabetic nephropathy and anxiety
symptoms in the Akita mouse model of type 1 diabetes.
Importantly, a recent epidemiological provided evidence that
diabetic kidney disease is a marker of brain dysfunction in patients
with type 1 diabetes [13]. We show that the treatment of Akita
mice with fisetin not only dramatically reduces diabetic kidney
damage but also lowers protein glycation by MG. The latter
observation is consistent with the idea that protein glycation may
be a major contributing factor to the complications of diabetes.
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Fisetin is orally active and has a number of properties in vitro,
including anti-oxidant and anti-inflammatory activities, which
have the potential to mitigate multiple complications of diabetes.
Akita mice have a mutation in the insulin gene and develop the
pathological characteristics of type 1 diabetes, including diabetic
nephropathy [14] and elevated anxiety symptoms [15], [16].
Therefore, it was asked whether fisetin could reduce these
complications. Four groups of mice were studied, 2 groups each
of wild type and Akita. Fisetin was fed to one set of control and one
set of Akita mice between the ages of 6 and 24 weeks in their food
at 0.05%, resulting in a daily dose of approximately 25–40 mg/kg.
This dose of fisetin was chosen based on earlier studies on fisetin
and cognitive function in mice [17]. Male Akita mice develop
hyperglycemia by 4 weeks of age [18]. We tested blood glucose in
all animals at 12 weeks and again before sacrificing the animals
at 24 weeks. At this time, blood glucose and HbA1c were
significantly elevated in the Akita mice (Table 1). These changes
were not affected by the presence of fisetin in the diet. The Akita
mice also showed significant weight loss relative to their wild type
counterparts and this was also not altered by fisetin in the diet.
Fisetin had no effect on blood glucose and HbA1c levels in the
wild type mice.
Fisetin reduces kidney damage in diabetic mice
Kidneys of Akita mice were significantly heavier than those of
wild type mice, consistent with the hypertrophy associated with
diabetic nephropathy in this strain of mice [14]. The diabetes-
induced increase in kidney size was significantly reduced by fisetin
(Fig. 1A). Fisetin had no effect on kidney weight in wild type mice.
In agreement with the increase in kidney weight, urine analysis
revealed significant albuminuria in the Akita mice that was almost
completely prevented by the presence of fisetin in the diet (Fig. 1B).
Fisetin had no effect on the albumin/creatinine ratio in wild type
mice.
Capillary lumen area, glomerular volume and PAS positive
mesangial matrix area were all significantly increased in the
kidneys of Akita mice as compared to wild type mice but not in the
kidneys of fisetin-treated Akita mice (Fig. 1C–I).
Fisetin protects diabetic mice from anxiety-associated
behavior
CNS dysfunction is another complication of diabetes. Although
cognitive impairment is associated with long-term diabetes in
humans [19] and is seen in some mouse models of type 1 diabetes
[20], [21], we saw no deficits in behavior in the Akita mice using
the Morris water maze, an assay of spatial learning and memory
(not shown), consistent with an earlier study [22]. However, Akita
mice display significantly decreased locomotor activity in the open
field test coupled with a significantly increased time of immobi-
lization [15]. These results were interpreted as indicative of
anxiety behavior, a CNS complication of many patients with
diabetes [16]. As shown in Figure 2, we confirmed these results
with the Akita mice. Furthermore, Akita mice fed fisetin showed a
significant reduction in these anxiety-related symptoms with both
the distance traveled and time ambulatory in the open field test
restored to near normal values. Fisetin had no effect on the
behavior of the wild type mice in the open field test.
Fisetin reduces markers of oxidative stress
To gain better insight into the biochemical basis of the kidney
pathology and its improvement by fisetin, we examined a number
of markers in the kidney that are related to oxidative stress. The
thiobarbituric acid reactive substances (TBARS) assay measures
the levels of lipid hydroperoxides. Thus, it is both a general
indicator of oxidative stress and also a surrogate marker of GSH
availability since lipid hydroperoxides are specifically removed by
glutathione peroxidase 4, which is absolutely dependent on GSH
[23]. Kidney TBARS levels were increased approximately 2-fold
in the Akita mice relative to wild type mice and this was prevented
by feeding fisetin (Fig. 3A). Fisetin has no effect on TBARS levels
in the wild type mice.
Osteopontin (OPN), a multifunctional phosphoglycoprotein and
pro-fibrotic adhesion molecule, is upregulated in the kidneys of
diabetic mice and humans, possibly by increases in oxidative stress
[24], and is a critical mediator of diabetic nephropathy [25]. As
shown in Figure 3B, OPN protein expression was upregulated ,2
fold in the Akita mice. The up-regulation of OPN in the Akita
mice was prevented by fisetin treatment. Fisetin had no significant
effect on OPN expression in the wild type mice.
As noted above, the pathological features of diabetic kidney
include markers of oxidative stress [26] and fisetin has the ability
to maintain the level of the cells’ major antioxidant, GSH, under
conditions of oxidative stress [5]. The rate-limiting step in GSH
synthesis is catalyzed by glutamate cysteine ligase (GCL). Figure 3C
shows that diabetes decreased the level of GCL and this was
restored by fisetin. There was, however, no change in total GSH
levels in the kidney of any of the four groups of animals (not
shown), suggesting that the maintenance of GSH homeostasis is
dependent on GSH availability rather than steady state GSH
levels [27].
An additional marker for oxidative stress that has been
implicated in the complications of diabetes is the receptor for
advanced glycation end products (RAGE). Activation of RAGE is
pro-oxidant and pro-inflammatory and is being investigated as a
therapeutic target for diabetic complications [28]. Figure 3D
shows that RAGE is highly elevated in the Akita mouse kidneys
and that fisetin significantly lowers RAGE expression. Since
elevated RAGE is also a physiological response to both
inflammation and protein glycation, we examined another
indicator of inflammation, the acute phase response (APR) protein
C-reactive protein (CRP), in the blood of the Akita and control
mice. CRP is a blood marker for the chronic systemic
inflammation associated with diabetes and elevated serum CRP
is also associated with both a decline in cerebral integrity and
cognitive function [29]. As shown in Figure 4A, CRP was
significantly increased in the plasma of Akita mice and this
increase was attenuated by the fisetin-rich diet. In contrast to
humans, the major APR protein in mouse blood is serum amyloid
P (SAP) rather than CRP [30] although the expression of both
proteins is coordinately regulated by the same transcription factor
[31]. As shown in Figure 4A, SAP was regulated in a manner very
Table 1. Metabolic Parameters at the end of the study.
Phenotype Weight (g) Blood Glucose (mg/dl) HbA1c (%)
Wild type 29.562.2 52.2632 4.960.2
Wild type + fisetin32.863.1 73.0629 5.260.4
Akita 23.961.7* 591.4678* 17.763.5*
Akita + fisetin 23.062.3* 560.1686* 16.061.6*
Statistical analysis by one-way ANOVA followed by Dunnett’s post-hoc test to
compare all groups against wild type. Data are mean 6 SD of N=5–7 per
group.
*=P,0.001 vs. wild type.
doi:10.1371/journal.pone.0021226.t001
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PLoS ONE | www.plosone.org 2 June 2011 | Volume 6 | Issue 6 | e21226Figure 1. Fisetin reduces the consequences of diabetes in Akita mice. Male Akita mice were fed control diet or fisetin (0.05%) for 18 weeks
beginning at 6 weeks of age. (A) Kidney hypertrophy was assessed by weighing the kidneys and normalizing the kidney weight to the relative weight
of the mice. (B) Kidney function was assessed by measuring the albumin/creatinine ratio in the urine. Fisetin reduced diabetes-induced renal
hypertrophy and albuminuria. Capillary lumen area, glomerular volume and PAS positive mesangial matrix area were increased in Akita mouse
kidneys (E, F: +fisetin) compared with wild type mice (C, D: +fisetin). The increase in capillary lumen area (G) (p,0.05) and glomerular volume in the
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reflects a systemic inflammatory response.
To determine the relationship between kidney dysfunction and
systemic inflammation as indicated by CRP levels, we compared
the albumin/creatinine ratio in the urine of 6 and 9 week old Akita
mice to their plasma CRP levels. As shown in Figure 4B, there was
a close association between the increase in plasma CRP and
albuminuria. Furthermore, while the 9-week old Akita mice
showed a significant increase in both plasma CRP and
albuminuria, this was largely blocked by the feeding of fisetin
beginning at 6 weeks of age.
Fisetin reduces MG-dependent protein glycation
Because RAGE expression is elevated by protein glycation and
reduced by fisetin (Fig. 3D), we investigated whether fisetin inhibits
MG-dependent protein glycation, a potential causative agent in
the complications of diabetes [11]. Proteins glycated by MG were
assayed in kidney homogenates and whole blood of Akita mice by
Western blotting using a monoclonal antibody against the N-
acetyl-N(5-hydro 5-methyl)-4 imidazolone adduct of MG [32].
Figure 5A shows that there is a significant increase in MG-glycated
proteins in the kidneys of Akita mice that is reduced to control
levels in mice fed fisetin. There is also a significant increase in MG-
glycated hemoglobin in Akita mice (Fig. 5B). Fisetin significantly
lowers the level of MG-glycated hemoglobin in wild type mice and
reduces it in Akita animals (Fig. 5B). There is not, however, an
increase in the ratio of MG-glycated to total hemoglobin in the
Akita animals because hemoglobin levels are also increased,
perhaps as a compensatory mechanism for the protein damaged
by glycation. The reduction of MG-glycated hemoglobin by fisetin
is, however, physiologically important because glycated proteins
increase oxidative stress and inflammation by the activation of
RAGE. In contrast, there is no significant change in the HbA1c
values in fisetin-treated mice (Table 1). However, the HbA1c
assay, which is used as an index of blood glucose levels in diabetic
individuals, detects chemically reversible, early glycosylation
products rather than irreversible AGEs [33]. In addition, fisetin
increases both the amount and activity of Glo-1 in kidney tissue
(Fig. 5B and C).
It is possible that the ability of fisetin to lower MG-dependent
protein glycation in the kidney and blood is independent of a
direct effect on MG-dependent glycation at the cellular level. To
rule out this possibility, the ability of fisetin to inhibit MG-
dependent protein glycation caused by GSH depletion and by
high glucose was examined in cultured cell lines. HT22 is a nerve
cell line in which exogenous glutamic acid (GA) inhibits cystine
uptake which is required in its reduced form for GSH synthesis.
GSH depletion leads to a type of programmed cell death called
oxytosis [34] and it also leads to the accumulation of MG-glycated
proteins (Fig. 5D). However, in the presence of 2 mM fisetin, MG-
dependent protein glycation is greatly reduced. Similarly, high
glucose leads to an increased flux of glucose through the glycolytic
pathway, increased MG formation and more proteins glycated by
MG [10]. When kidney mesangial cells grown in 5 mM glucose
are exposed to 25 mM glucose, there is an increase in MG-
dependent protein glycation that is reduced by 10 mM fisetin
(Fig. 5D). These data show that fisetin has a direct effect at the
cellular level on protein glycation by MG that is independent of
the diabetic state in animals.
Figure 2 shows that fisetin has the ability to reduce an
experimental index of anxiety, an indicator of CNS dysfunction,
in Akita mice. Therefore, it was asked whether fisetin alters the
parameters of MG metabolism in the brain as it does in the kidney.
Figure 6A shows that the enzymatic activity of Glo-1 is decreased
in the cortices of Akita mouse brains and is elevated by fisetin.
Consistent with the decrease in Glo-1 activity in the Akita mouse
Figure 2. Fisetin reduces an experimental index of anxiety in Akita mice. Male Akita mice were fed control diet or fisetin (0.05%) diet for 18
weeks beginning at 6 weeks of age. Locomotor activity was measured in the open field test. Decreased locomotor activity is an indicator of elevated
anxiety that is characteristic of diabetics in poor glycemic control. Fisetin restored (A) distance traveled and (B) time ambulatory to nearly control
levels. All data are mean 6 SD of n=5–7/group. *(p,0.05) and **(p,0.01) indicate significantly different from wild type or Akita alone as determined
by ANOVA followed by Tukey’s post test.
doi:10.1371/journal.pone.0021226.g002
Akita mouse kidneys was significantly different from controls (H) (p,0.001) and was largely prevented by fisetin. The PAS positive area was also
significantly increased in the Akita mouse kidneys (I) (p,0.05) while this difference was not significant in the Akita + fisetin kidneys. All data are mean
6 SD of n=5–7/group. *(p,0.05), **(p,0.01), ***(p,0.001) indicate significantly different from wild type or Akita alone as determined by ANOVA
followed by Tukey’s post test.
doi:10.1371/journal.pone.0021226.g001
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the cortex (Fig. 6B) that is decreased to control levels by fisetin.
Furthermore, there is also a highly significant decrease in MG-
glycated proteins in the cortex from fisetin-treated wild type mice
(Fig. 6B). Finally, both Glo-1 and GCL protein levels are
decreased in the cortices of Akita mouse brains relative to those
Figure 3. Fisetin reduces biochemical changes in Akita mouse kidneys. (A) The diabetes-dependent increase in TBARS is prevented by
fisetin. Kidneys from wild type, wild type + fisetin, Akita and Akita + fisetin mice were homogenized in PBS containing phosphatase and protease
inhibitors and equal amounts of extract were assayed for TBARS. Kidney samples from 6–7 mice were analyzed and the amount of TBARS normalized
to protein. (B) The diabetes-dependent up-regulation of osteopontin (OPN) is prevented by fisetin. Kidneys from wild type, wild type+fisetin, Akita
and Akita + fisetin mice were homogenized in PBS containing phosphatase and protease inhibitors and equal amounts of protein were analyzed by
SDS-PAGE and Western blotting with an antibody to OPN and actin as a loading control. The expression of GCL (C) and the RAGE receptor (D) in
kidneys were analyzed by Western blotting as described in (B). Kidney samples from 6–7 mice per group were analyzed and the average intensity of
the GCL, RAGE, and OPN bands normalized to actin is shown in the graphs. A representative blot is shown for each. ***(p,0.001), **(p,0.01) and
*(p,0.05) indicate significantly different from wild type or Akita alone as determined by ANOVA followed by Tukey’s post test.
doi:10.1371/journal.pone.0021226.g003
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diabetic mice. Together these data show that the regulation of MG
metabolism by fisetin is similar in brain and kidney and support
the recent observation that kidney disease is a marker for cognitive
problems in patients with type 1 diabetes [13].
Discussion
The major findings of this study are that fisetin can prevent the
development of several indices of diabetic complications when
orally administered to type 1 diabetic Akita mice and that this
therapeutic outcome is associated with a decrease in MG-
dependent protein glycation. Since a single molecule is effective
against multiple manifestations of two distinct complications of
diabetes, these results lend support to the hypothesis that many of
the complications of diabetes share common pathogenic mecha-
nisms [3]. Fisetin increases the expression of both the rate-limiting
enzyme in GSH synthesis, GCL, and the MG-degrading enzyme,
Glo-1, that requires GSH as a co-factor. Since fisetin concomi-
tantly reduces protein glycation by MG, it is likely that MG-
dependent protein glycation contributes to both the neurological
and kidney complications of diabetes. These results also provide
evidence that a single, multi-target compound is a viable approach
to the treatment of distinct, tissue-specific diabetic complications.
Although overexpression of Glo-1 has been shown to reduce
indices of diabetic complications both in vitro [32], [35] and in vivo
[36], it has not been clear how to translate those results into the
clinic. In addition, a number of flavonoids [37] and other natural
products such as curcumin [38] have been reported to inhibit Glo-
1 activity as has the insulin-sensitizing drug troglitazone [39]. In
contrast, not only does fisetin increase Glo-1 levels and activity but
it also increases the synthesis of its essential co-factor GSH. Thus,
the use of fisetin represents a unique approach to enhancing the
function of the glyoxalase pathway.
We employed the Akita model of type 1 diabetes to obviate any
concerns about direct organ toxicity arising from the use of
diabetogenic chemicals. As reported previously, the Akita mice
showed a number of changes consistent with diabetic nephropathy
[14], [25]. In our study, these included significant increases in
kidney weight, TBARS levels and OPN expression as well as an
increase in the urine albumin/creatinine ratio. However, while the
effects of diabetes on kidney weight and urine albuminuria were
marked, increases in glomerular volume and mesangial score were
much less robust, suggesting that these mice exhibit a slowly
progressing, mild functional nephropathy. Most of the biochemical
and functional consequences of diabetes in the kidney were
reduced or prevented by fisetin. The effects of fisetin on OPN
expression are consistent with a recent study showing that OPN
deletion on the Akita background attenuated the effects of
hyperglycemia on multiple aspects of diabetic nephropathy
including kidney weight and proteinuria [25] suggesting that this
protein may be a key target of the actions of fisetin.
Although less well studied than other complications, the CNS
complications of diabetes can also have a significant impact on the
Figure 4. Fisetin reduces markers of inflammation in Akita mice. (A) Male Akita mice were fed control diet or fisetin (0.05%) diet for 18 weeks
beginning at 6 weeks of age. C-reactive protein (CRP) and serum amyloid P (SAP) were measured in plasma by Western blotting. Fisetin reduced
plasma CRP and SAP levels in the Akita mice to nearly the levels in the control mice. All data are mean 6 SD of n=5–7/group. ***(p,0.001) indicates
significantly different from wild type or Akita alone as determined by ANOVA followed by Tukey’s post test. (B) Age dependent increases in plasma
CRP and urine albumin/creatinine ratio (ACR). Male Akita mice were first tested at 6 weeks of age and then fed control diet or fisetin (0.05%) for 3
weeks prior to re-testing. C-reactive protein (CRP) was measured in plasma by Western blotting. The albumin/creatinine ratio (ACR) in the urine was
determined using ELISAs. All data are mean 6 SD of n=8–10/group. **(p,0.01 - 6 week) indicates significantly different from wild type as
determined by t-test. **(p,0.01) and ***(p,0.001) indicate significantly different from wild type or Akita alone as determined by ANOVA followed by
Tukey’s post test.
doi:10.1371/journal.pone.0021226.g004
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among the natural products previously tested for their effects on
diabetic complications in that it also exhibits neurotrophic and
neuroprotective properties in CNS neurons [40], enhances
memory [17] and improves behavioral outcomes following
ischemic stroke [41]. The neurotrophic activity of fisetin may
contribute, along with its ability to reduce MG-dependent protein
glycation, to its efficacy against the reduced open field behavior
seen in the Akita mice, as efficacy cannot be attributed to
improvement of systemic indices of diabetes.
Methylglyoxal is a toxic a-oxoaldehyde glycating agent mostly
formed from triose-phosphates and it has been suggested that MG-
Figure 5. Fisetin reduces MG-dependent protein glycation in the kidney and blood. (A) Kidneys were homogenized in PBS containing
phosphatase and protease inhibitors and equal amounts of protein were analyzed by SDS-PAGE and Western blotting with an antibody to MG and
actin as a loading control. The entire gel as shown was scanned and the total density normalized to actin. Four to 6 animals were used per group for
quantifying band densities with 2 representative kidneys per group shown. (B) Either whole blood was assayed by Western blotting with an anti-MG
antibody or kidney tissue with an anti-glyoxylase 1 antibody. The major MG-glycated protein in blood was hemoglobin (shown) and its loading
control is total hemoglobin (a and b). Glyoxylase 1 expression was normalized to actin. (C) The activity of glyoxylase 1 was measured and is expressed
in units. One unit is the amount of activity required to produce 1 mmole of S-D-lactoylglutathione/min/mg protein. ***(p,0.001), **(p,0.01) and
*(p,0.05) indicate significantly different from wild type or Akita alone as determined by ANOVA followed by Tukey’s post test. (D) Exponentially
dividing HT22 cells were exposed to 5 mM glutamic acid (GA) with or without 2 mM fisetin (Fis) for 8 h. The cells were lysed in SDS sample buffer and
equal amounts of protein were analyzed by SDS-PAGE and Western blotting with an antibody to MG and actin as a loading control (n=3). The kidney
mesangial cell line MES13 was grown in 5 mM glucose (glu) (C is control) and some cells transferred to 25 mM glucose plus or minus 10 mM fisetin
(Fis) for 8 h. The cells were lysed is SDS sample buffer and equal amounts of protein were analyzed by SDS-PAGE and Western blotting with an
antibody to MG and actin as a loading control (n=3). For both cell lines, the entire gels as shown were scanned and the total densities normalized to
actin. Significant differences were determined by ANOVA followed by Tukey’s post test. **p,0.01; *** p,0.001.
doi:10.1371/journal.pone.0021226.g005
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pathology associated with diabetic complications [11], [35], [12].
It is shown here that glycation of proteins by MG is increased in
Akita blood, kidney and brain, and that this increase is reduced by
fisetin (Fig. 5A, B; Fig. 6B). Elevated exogenous glucose increases
the rate of glycolysis and the greater the flux of glucose through the
glycolytic pathway, the greater amount of MG is produced [10]. In
addition, if glycolysis is inhibited downstream of the triose-
phosphates by the oxidative inactivation of GAPDH, there is a
backward flux of trioses and increased MG production. Oxidative
stress is elevated in diabetes [3] (Fig. 3A), GAPDH is inactivated
under conditions of mild oxidative stress [42], and fisetin has dual
antioxidant functions by maintaining intracellular GSH levels and
acting as a direct antioxidant [5]. Glo-1 is the rate-limiting enzyme
in the removal of MG and it is dependent upon reducing
equivalents derived from NADPH through its reduction of
oxidized GSH. Fisetin also increased the expression and activity
of Glo-1 as well as GCL, the rate-limiting enzyme in GSH
synthesis (Fig. 3C, Fig. 5B, C, Fig. 6A, C). Oxidative stress and
protein glycation caused by hyperglycemia also induce the
expression of the RAGE protein in the kidney, which is greatly
reduced by fisetin (Fig. 3D). In summary, these data argue that
MG-dependent protein glycation is a major therapeutic target of
fisetin.
Fisetin also exhibits a number of related properties that may
contribute to its efficacy in addition to the reduction of MG-
dependent protein glycation. The increase in plasma CRP and
SAP levels seen in our Akita mice and its prevention by fisetin
treatment are novel findings, suggesting that the Akita mice are in
a systemic pro-inflammatory state that can be prevented by fisetin.
This conclusion is supported by the data from the 6 and 9 week
old Akita mice which showed an increase in plasma CRP with age
which was blocked by fisetin (Fig. 4B). Increases in markers of
systemic inflammation are associated with both oxidative stress in
the microvasculature and diabetic complications [43]. Protein
glycation is a major contributor to inflammation because it
activates RAGE, resulting in both oxidative stress via NADPH
oxidase and inflammation through the activation of the pro-
inflammatory transcription factor nuclear factor kappa B [8].
Furthermore, CRP can directly increase ROS production by
endothelial cells [44]. Overexpression of OPN is also associated
with chronic inflammation [45], oxidative stress [46] and GSH
depletion [46]. An interaction between systemic and tissue specific
inflammation is supported by the results showing a coordinated
increase in albuminuria and plasma CRP in Akita mice as they
age. The effects of fisetin on both plasma levels of CRP and kidney
expression of OPN as well as albuminuria suggest that it has both
systemic and tissue-specific effects on inflammation that can
reduce the consequences of diabetes. These anti-inflammatory
effects may also be related to the reduction in anxiety associated
behavior seen in the fisetin-treated Akita mice since hypothalamic
pituitary-adrenal axis activation, which is implicated in anxiety-
associated behavior in the Akita mice [15], is induced under pro-
inflammatory conditions [47]. Fisetin therefore has the potential to
disrupt both pro-inflammatory and pro-oxidative pathways that
are implicated in the complications of diabetes.
Flavonoids are extensively metabolized following oral consump-
tion resulting in glucuronidated, sulfated and methylated metab-
olites (for reviews see [48], [49]). The metabolism of fisetin was
recently characterized in rats following intravenous and oral
administration [50]. Following both types of administration, the
levels of free fisetin in serum declined rapidly while the levels of
sulfated/glucuronidated fisetin increased. Following oral adminis-
tration at 50 mg/kg, the serum concentration of fisetin sulfates/
glucuronides was maintained at ,10 mM for .24 hr. When tested
in an assay for antioxidant activity, the fisetin sulfates/glucuro-
nides showed somewhat reduced but still significant activity as
compared to free fisetin [50].
In summary, we show that oral administration of fisetin
significantly reduced indices of two of the complications of
diabetes. Fisetin also coordinately decreased the level of MG-
dependent protein glycation in kidney, brain and blood, suggesting
that MG may be a common pathological factor that contributes to
multiple complications of diabetes. Therefore, fisetin or a synthetic
derivative might be useful for the treatment of diabetic patients.
Although fisetin is not particularly abundant in many fruits and
vegetables, the incorporation of significant quantities of fisetin-rich
foods into the diet of diabetic patients might provide an alternative
Figure 6. Fisetin reduces MG-dependent protein glycation in the cortex. Brain cortical extracts were prepared and analyzed exactly as for
the kidney shown in Fig. 5 with 6 to 8 animals per group. (A) Glyoxylase 1 enzymatic activity. (B) Protein analyzed by SDS-PAGE and Western blotting
with an antibody to MG with actin as a loading control. The entire gel as shown was scanned and the total density normalized to actin. (C) Western
blotting with anti-GCL and Glo-1 antibodies. In B and C, the data are presented graphically as relative band density of indicated protein over actin.
***(p,0.001), **(p,0.01) and *(p,0.05) indicate significantly different from wild type or Akita alone as determined by ANOVA followed by Tukey’s
post test.
doi:10.1371/journal.pone.0021226.g006
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strawberries with 5–10 fold lower levels in apples and persimmons
[51] and smaller amounts in kiwi fruit, peaches, grapes, tomatoes,
onions and cucumbers. The bioavailability of fisetin from these
sources has yet to be studied but may be a fruitful area of research.
Materials and Methods
Mice
C57BL/6-Ins2
Akita (Akita) mice in the C57BL/6 background
and C57BL/6 control mice were purchased from The Jackson
Laboratories (Bar Harbor, ME). Ins2
Akita is a model of type 1
diabetes [52]. The Akita spontaneous mutation is an autosomal
dominant mutation in the insulin II gene. This missense mutation
results in an amino acid substitution that corresponds to the
seventh amino acid position of the insulin II A chain. Male mice
were maintained under a 12-h light/dark cycle and fed a high fat
mouse chow (30E, Harlan) without or with fisetin supplementation
(0.05%) ad libitum beginning at 6 weeks of age until they were
killed at 24 weeks of age. During the course of the study 2/9 Akita
and Akita+fisetin mice died from undetermined causes. Based on
average weekly food consumption and body weight, the wild type
mice received ,25 mg/kg fisetin/day while the diabetic mice ate
more food and received ,40 mg/kg/day. The animal studies and
the protocols were approved by the IACUC of the Salk Institute
(protocol #09-025; approved 5/1/2009).
Blood was taken for determination of glucose, hemoglobin
glycation and markers of inflammation at 3 months and then just
before sacrifice. Beginning 1 week before sacrifice, urine was
collected at exactly the same time of day for 5 days and pooled for
analysis. In parallel studies, blood and urine samples were
obtained from mice at 6 and 9 weeks of age.
Measurement of urine albumin and creatinine
Urine albumin concentration was determined by competitive
enzyme-linked immunoadsorbent assay using an Albuwell M kit
(Exocell, Philadelphia, PA). Urine creatinine concentration was
determined by Jaffe’s reaction of alkaline picrate with creatinine
using a Creatinine Companion kit (Exocell). Results are expressed
as the urinealbumin-to-creatinine ratio(micrograms permilligram).
Kidney Morphology
The harvested kidneys were fixed in buffered formalin. After
paraffin embedding, 3-micrometer sections were stained with PAS.
Morphometry of sections of kidneys was carried out as previously
reported [53]. Briefly, twenty-five randomly selected glomeruli in
the outer cortex of each kidney section were evaluated in a blinded
manner. An image of each glomerulus was overlaid with grids.
Each grid intersection was determined as one of the following:
capillary lumen, periodic acid-Schiff (PAS) positive mesangial area
or nucleus. To evaluate PAS positive area, the total number of
PAS positive grid intersections inside each glomerulus was
counted. The number of all the grid intersections was calculated
for glomerular size.
Kidney and Brain Protein Analysis
Kidneys or brain cortices were homogenized in phosphate
buffered saline containing protease and phosphatase inhibitors.
Equal amounts of protein, as determined by the BCA assay
(Pierce), were solubilized in SDS-sample buffer containing
0.1 mM Na3VO4 and 1 mM phenylmethylsulfonyl fluoride,
boiled for 5 min and either analyzed immediately or stored frozen
at 270uC. Proteins were separated on 10% SDS-polyacrylamide
gels and transferred to nitrocellulose. Equal loading and transfer of
the samples was confirmed by staining the nitrocellulose with
Ponceau-S. Transfers were blocked for 1 h at room temperature
with 5% nonfat milk in TBS/0.1% Tween 20 and then incubated
overnight at 4uC in the primary antibody diluted in 5% BSA in
TBS/0.05% Tween 20. The primary antibodies used were: rabbit
anti-osteopontin (AB10910; 1/10,000) and mouse anti-RAGE
(MAB5328; 1/12,500) from Millipore (Temecula, CA), mouse
anti-MG (Dr. Michael Brownlee; 1/1000), rabbit anti-GCL
(sc22663; 1/1000), rabbit anti-glyoxalase-1 (sc67351; 1/1000),
goat anti-hemoglobin a (sc31332, 1/1000) and goat anti-
hemoglobin b (sc31116, 1/1000) from Santa Cruz (Santa Cruz,
CA) and HRP-conjugated rabbit anti-actin (#5125, 1/20,000)
from Cell Signaling (Danvers, MA). The transfers were rinsed with
TBS/0.05% Tween 20 and incubated for 1 h at room
temperature in horseradish peroxidase-goat anti-rabbit or goat
anti-mouse (Biorad, Hercules, CA) diluted 1/5000 in 5% nonfat
milk in TBS/0.1% Tween 20. The immunoblots were developed
with the Super Signal reagent (Pierce, Rockford, IL).
TBARS Assay
Thiobarbituric acid reactive substances (TBARS), a measure of
lipid peroxidation, was assayed in kidney extracts using a kit
(Cayman Chemicals, Ann Arbor, MI) and by following the
manufacturer’s instructions.
Measurement of C-reactive protein and serum amyloid P
C-reactive protein and serum amyloid P levels were determined
by SDS-PAGE and Western blotting analysis of mouse plasma.
The primary antibodies used were goat anti-CRP (AF1829;
0.25 mg/ml) from R&D (Minneapolis, MN) and rabbit anti-SAP
(A00701; 1/1000) from GenScript (Piscataway, NJ).
Open field test
The open field test was performed using MED Associates
hardware and the Activity Monitor software according to the
manufacturer’s instructions (MED Associates Inc, St. Albans, VT,
USA). The open-field activity monitoring system contains a subject
containment environment (chamber), infrared (I/R) sources and
sensors. To perform the test, each mouse was placed in the testing
chamber and the activity tracked by the Activity Monitor software
for 30 min. The scanning was done every 50 ms.
Cell culture
The kidney mesangial cell line SV40 MES13 (ATCC #CRL-
1927) was grown as described in DME containing 5 mM glucose
[54]. The cells were then transferred to the same medium
containing 30 mM glucose and 8 h later the cells lysed in SDS
sample buffer and run on 12% polyacrylamide gels for Western
blotting using the anti-MG monoclonal antibody [32]. HT22
mouse hippocampal neurons were grown in DME plus 10% fetal
serum [55]. To deplete GSH, cells were exposed to 5 mM
glutamic acid and lysed in sample buffer as described above for
Western blotting with the anti-MG antibody.
Glyoxalase-1 assay
The glyoxalase-1 assay was performed using a spectrophoto-
metric method monitoring the increase in absorbance at 240 nm
due to the formation of S-D-lactoylglutathione for 2 min at 25uC.
The standard assay mixture contained 8 mM MG, 2 mM
glutathione, 10 mM magnesium sulfate and 50 mM phosphate
potassium, pH 6.6. Before initiating the reaction by adding the
kidney or brain extract (10–30 mg) to the assay mixture, the
mixture was allowed to stand for at least 2 min to ensure the
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PLoS ONE | www.plosone.org 9 June 2011 | Volume 6 | Issue 6 | e21226equilibration of hemithioacetal formation. One unit of activity is
defined as the formation of 1 mmol of S-D-lactoylglutathione/
min/mg cell protein. Protein concentration was determined by the
BCA assay.
Statistical Analysis
All groups were compared against each other using one-way
ANOVA followed by Tukey’s or Dunnett’s post-hoc test. Data are
presented as group mean 61 standard deviation.
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